User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

Interactions with Platform & by Email *

INTERACTIONS

Unique # Participated *

PARTICIPANTS

Responses Validated *

VALIDATIONS

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
Quantitative Techniques & Analytics.....I-2
  
   Product Definitions and Scope of Study.....I-3
Metered Dose Inhalers (MDIs).....I-3
Dry Powder Inhalers (DPIs).....I-3
  
   Others.....I-4
Nebulizers.....I-4
  
   Drug Delivery Technologies: A Primer.....II-1
Table 1: Worldwide Drug Delivery Market (2009): Percentage Share Breakdown of Revenue by Technology Segment (includes corresponding Graph/Chart).....II-1
Drug Delivery Technologies Turns Critically Important to Pharma Majors.....II-1
1$350
   The Need for Novel Drug Delivery Technologies From A Financial Standpoint.....II-21$100
   Pulmonary Drug Delivery: A Preferred, Non-Invasive Drug Administration Route.....II-3
Market Fundamentals: A Current Review.....II-3
1$100
   Respiratory Disorders: A Large & Mature Therapeutic Category.....II-41$100
   Widely Prescribed Inhalation Drugs for Asthma & COPD.....II-5
Inhaler Devices: An Integral Part of Pulmonary Drug Delivery.....II-5
Pulmonary Delivery of Systemic Drugs: A Future Growth Area.....II-5
1$100
   Delivering Macromolecules Through the Lungs: A Current Focus Area.....II-61$100
   Innovations in Inhalation Aerosols.....II-71$100
   Current Drugs in Pipeline: A Review.....II-8
Inhaled Drugs in Pipeline as of the Year 2008 & 2009.....II-8
2$125
   Noteworthy Trends & Issues.....II-10
Nanotechnology Makes its Presence Felt in Inhaled Drugs.....II-10
1$100
   Innovation in Inhaler Devices: A Key Differentiating Factor.....II-11
Innovation is the Name of the Game in the Nebulizer Segment.....II-11
1$100
   Nebulizers for Pediatric Care: Need of the Hour.....II-12
CFC Propellants Give Way to HFA.....II-12
1$100
   Chinks in MDI’s Armor Work in Favor of DPI Market.....II-13
Potential Challenges for DPI Market.....II-13
Combination Therapy: An Effective Strategy in Optimum Disease Management.....II-13
1$100
   Definition of Pulmonary Drug Delivery System.....II-14
Benefits of Pulmonary Drug Delivery Systems.....II-14
Therapeutic Benefits.....II-14
1$100
   Titration by Therapy.....II-15
Titration by Patient.....II-15
Dose Reproducibility.....II-15
High Bioavailability.....II-15
Other Key Advantages.....II-15
1$100
   Pulmonary Drug Delivery Devices.....II-16
An Overview of Key Features of Popular Inhalation Devices.....II-16
Inhalers.....II-16
Metered Dose Inhalers (MDIs).....II-16
1$100
   Working Principle of an MDI.....II-171$100
   CFC-Propellant based MDIs.....II-18
Ban on CFCs.....II-18
Use of Spacers in MDIs.....II-18
Benefits of Spacers.....II-18
1$100
   Pros & Cons.....II-19
Advantages.....II-19
Unique Benefits of pMDIs.....II-19
Limitations.....II-19
Issues.....II-19
1$100
   MDIs & Future.....II-20
Dry Powder Inhalers (DPIs).....II-20
Inspiratory Flow Rate in DPIs.....II-20
1$100
   Working Principle of DPIs.....II-21
Deaggregation in Dry Powder Inhalers (DPIs).....II-21
Types of DPIs.....II-21
Passive DPI.....II-21
Active DPI.....II-21
1$100
   Single-dose DPIs.....II-22
Multi-dose DPIs.....II-22
Other Types.....II-22
Benefits of DPIs.....II-22
1$100
   Limitations.....II-23
Issues.....II-23
In a nutshell.....II-23
Comparison with MDIs.....II-23
1$100
   Nebulizers.....II-24
Working Principle of a Nebulizer.....II-24
1$100
   Use of UDMs in Nebulizers.....II-25
Types of Nebulizers.....II-25
Ultrasonic Nebulizers.....II-25
1$100
   Gray Areas.....II-26
Benefits.....II-26
Limitations.....II-26
1$100
   Pneumatic Nebulizers.....II-27
Breath-Actuated Nebulizers.....II-27
Continuous Nebulization.....II-27
Active Venturi Nebulizers.....II-27
New Designs for Improved Nebulizer Performance.....II-27
1$100
   Limitations of Nebulizers.....II-28
Factors Influencing Clinical Effectiveness of Inhalation Device.....II-28
Device Factors.....II-28
Patient Factors.....II-28
Drug Factors.....II-28
1$100
   The Respiratory System.....II-29
Pulmonary Drug Delivery – An Overview.....II-29
Asthma and COPD – Major Respiratory Disease Conditions.....II-29
Asthma: Primary Respiratory Syndrome.....II-29
1$100
   Trigger Factors.....II-30
Magnitude of Disease.....II-30
1$100
   Chronic Obstructive Pulmonary Disease.....II-31
Magnitude of Disease.....II-31
Treatment of Asthma and COPD.....II-31
Methods of Drug Delivery through Pulmonary Route.....II-31
1$100
   Aerosols Systems.....II-32
Intratracheal Inhalation.....II-32
Insufflation.....II-32
Pulmonary Delivery Approaches.....II-32
1$100
   Controlled Release.....II-33
Drug Medications for Treating Asthma and COPD.....II-33
Bronchodilators (Acute Reliever Drugs).....II-33
1$100
   Categories of Bronchodilators.....II-34
Short acting beta-agonists.....II-34
Long acting beta-agonists.....II-34
1$100
   Anti-cholinergics.....II-351$100
   Methylxanthines.....II-36
Combination Bronchodilators.....II-36
1$100
   Available Inhaled Locally Acting Drugs.....II-37
Anti-Inflammatory Medication (Controllers or Preventers).....II-37
Corticosteroids.....II-37
1$100
   Inhaled Corticosteroids in Asthma.....II-38
Inhaled Corticosteroids in COPD.....II-38
1$100
   Anti-Leukotrienes.....II-39
Innovative Therapeutic Approaches.....II-39
Combination Therapeutics.....II-39
2$125
   Pearl Therapeutics Announces Phase II Trials of Glycopyrrolate Inhalation Aerosol in
  COPD.....II-41
PARI Receives Patent for Vortex Holding Chamber.....II-41
Schering-Plough Obtains Approval for Asmanex in Japan.....II-41
SkyePharma Inc Receives FDA Communication on Flutiform.....II-41
1$100
   Almirall Announces Positive Results of Phase III Eklira.....II-42
MicroDose Therapeutx Initiates Phase 1 Study with Inhaled Atropine.....II-42
PARI Pharma Announces Successful Phase Ib Results for Inhaled L-CsA.....II-42
PARI Respiratory Launches PEP S.....II-42
1$100
   3M Drug Delivery Systems Rolls Out 3M Conix DPI, 3M Taper DPI.....II-43
Akela Pharma Achieves Third Milestone in Fentanyl TAIFUN® Phase III Study.....II-43
Vectura Group Announces Phase III Trials for NVA237, QVA149.....II-43
1$100
   Novartis Gets EU Approval for Onbrez® Breezhaler®.....II-44
Novartis Gets Complete Response Letter for QAB149, from US FDA.....II-44
Novartis Obtains EU Approval for Xolair® for Treating Severe Asthma in Children
  Under 11 Years.....II-44
AstraZeneca Gets FDA Complete Response Letter for Symbicort in Paediatric
  Patients.....II-44
AstraZeneca Gets FDA Approval for Symbicort in COPD.....II-44
1$100
   3M Drug Delivery Systems Unveils 3M Face Seal Valve, 3M Plasma Coating
  Technology.....II-45
Nanotechnology Victoria, Monash University Develops SAW Generated Mechanism.....II-45
RTS Life Science Rolls Out Automated Inhaler Testing Solution.....II-45
1$100
   Eli Lilly &Co and Alkermes Abandon Inhaled Insulin Development Deal.....II-46
Novo-Nordisk Drops Development Plan of Inhaled Insulin.....II-46
Concomitant Use of Tiotropium, Nebulized Formoterol Fumarate to Relieve COPD
  Symptoms.....II-46
Advair Gets FDA Nod for Advair 250/50.....II-46
1$100
   Dainippon Sumitomo Concludes Acquisition of Sepracor.....II-47
MicroDose Therapeutx Acquires ViroPharma Investigational Compounds.....II-47
Sepracor Grants Non-Exclusive License for XOPENEX® to Teva and Barr.....II-47
Skyepharma, Novartis Terminate Formoterol Certihaler Deal.....II-47
Tidal Air to Sell Matrix Aerosol Delivery System.....II-47
Battelle Memorial Institute Purchases Assets of Ventaira Pharmaceuticals Inc.....II-47
1$100
   Aptar Pharma to Roll Out Pulmonary & Nasal Devices In India.....II-48
3M Drug Delivery Systems Unveils New Singaporean Facility.....II-48
Forest Laboratories, Almirall, Extend Collaboration for LAS100977.....II-48
MicroDose Therapeutx, Merck Expand Collaboration Deal.....II-48
AstraZeneca Sells API Facility to Minakem.....II-48
ALR Technologies, Pari Enter Into Agreement.....II-48
1$100
   Akela Adds Amendment Into Fentanyl TAIFUN® License Deal with Teikoku Seiyaku.....II-49
Novartis, Schering-Plough Revise Collaboration Terms.....II-49
Astellas, AstraZeneca Ink Co-Promotion Agreement for Symbicort Turbuhaler.....II-49
Iroko Cardio Inks Distribution Agreement with Chiesi Farmaceutici.....II-49
Novartis Completes Acquisition of Nektar’s Pulmonary Business.....II-49
1$100
   3M, Cambridge Consultants Forge Licensing Deal for DPI Technology.....II-50
Savara Relocates Headquarters to Texas.....II-50
GSK to Take Over Genelabs Technologies Inc.....II-50
Novo Nordisk Hand Over Inhaled Insulin Patents to Aradigm.....II-50
Sepracor Enters Into Agreement with Arrow International.....II-50
1$100
   Royal Philips Electronics Acquires Medel, Melhk.....II-51
Aerogen Concludes Management Buyout from Nektar.....II-51
Valois Pharma Bags Multi Million Contract.....II-51
1$100
   3M Drug Delivery Systems Division (USA).....II-52
Akela Pharma Inc (Canada).....II-52
Alkermes, Inc. (USA).....II-52
Aradigm Corporation (USA).....II-52
1$100
   AstraZeneca Plc (UK).....II-53
Baxter International Inc. (USA).....II-53
1$100
   Chiesi Farmaceutici SpA (Italy).....II-54
Consort Medical Plc (UK).....II-54
1$100
   Dey Pharma L.P. (USA).....II-55
GlaxoSmithKline Plc (UK).....II-55
1$100
   Graceway Pharmaceuticals, LLC (USA).....II-56
NovartiS AG (Switzerland).....II-56
Oriel Therapeutics, Inc. (USA).....II-56
1$100
   Sepracor, Inc. (USA).....II-57
SkyePharma Plc (UK).....II-57
Valois S.A.S. (France).....II-57
1$100
   Vectura Group Plc (UK).....II-581$100
   Table 2: World Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Geographic Region - US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-591$350
   Table 3: World Historic Review for Pulmonary Drug Delivery Technologies by Geographic Region - US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-601$350
   Table 4: World 13-Year Perspective for Pulmonary Drug Delivery Technologies by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets for Years 2003, 2009, and 2015 (includes corresponding Graph/Chart).....II-611$350
   By Product Segments.....II-62
Table 5: World Recent Past, Current and Future Analysis for Metered Dosage Inhalers (MDIs) by Geographic Region - US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-62
1$350
   Table 6: World Historic Review for Metered Dosage Inhalers (MDIs) by Geographic Region - US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-631$350
   Table 7: World 13-Year Perspective for Metered Dosage Inhalers (MDIs) by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets for Years 2003, 2009, and 2015 (includes corresponding Graph/Chart).....II-641$350
   Table 8: World Recent Past, Current and Future Analysis for Dry Powder Inhalers (DPIs) by Geographic Region - US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-651$350
   Table 9: World Historic Review for Dry Powder Inhalers (DPIs) by Geographic Region - US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-661$350
   Table 10: World 13-Year Perspective for Dry Powder Inhalers (DPIs) by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets for Years 2003, 2009, and 2015 (includes corresponding Graph/Chart).....II-671$350
   Table 11: World Recent Past, Current and Future Analysis for Other Pulmonary Drug Delivery Technologies by Geographic Region - US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-681$350
   Table 12: World Historic Review for Other Pulmonary Drug Delivery Technologies by Geographic Region - US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-691$350
   Table 13: World 13-Year Perspective for Other Pulmonary Drug Delivery Technologies by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets for Years 2003, 2009, and 2015 (includes corresponding Graph/Chart).....II-701$350
   A. Market Analysis.....III-1
Outlook.....III-1
Current Market Scenario.....III-1
Major Growth Areas/Indicators.....III-1
Respiratory Diseases.....III-1
1$75
   Cancer.....III-2
Cystic Fibrosis.....III-2
HFA Albuterol Eats into CFC Inhalers Market.....III-2
1$75
   Table 14: US Albuterol Inhalers Market in Aerosol Beta Agonists Category (2008 & 2009): Percentage Share Breakdown of Revenue by Product Type (includes corresponding Graph/Chart).....III-3
New & Popular DPIs in the US.....III-3
Nebulizers: Displaying Promising Growth.....III-3
1$200
   Table 15: US Nebulizers Market (2008): Percentage Share Breakdown of Revenues by Segment (includes corresponding Graph/Chart).....III-4
Role of FDA.....III-4
Key Market Share Findings.....III-4
Table 16: US Bronchodilators Market (2008): Percentage Share Breakdown of Revenues by Key Players (includes corresponding Graph/Chart).....III-4
1$200
   Table 17: US Anti-Inflammatory Market (2008): Percentage Share Breakdown of Revenues by Key Players (includes corresponding Graph/Chart).....III-5

Table 18: US Bronchodilators Market (2009): Percentage Share Breakdown of Revenues by Segment (includes corresponding Graph/Chart).....III-5

Table 19: US Anti-Inflammatory Market (2008): Percentage Share Breakdown of Revenues by Segment (includes corresponding Graph/Chart).....III-5
1$200
   Product Launches/Developments.....III-62$125
   Strategic Corporate Developments.....III-83$175
   Select Players.....III-113$175
   B. Market Analytics.....III-14
Table 20: US Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-14
1$200
   Table 21: US Historic Review for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-151$200
   Table 22: US 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart).....III-161$200
   A. Market Analysis.....III-17
Outlook.....III-17
Product Launch.....III-17
Strategic Corporate Developments.....III-17
Akela Pharma Inc – A Key Canadian Player.....III-17
1$75
   B. Market Analytics.....III-18
Table 23: Canadian Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-18
1$200
   Table 24: Canadian Historic Review for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-191$200
   Table 25: Canadian 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart).....III-201$200
   A. Market Analysis.....III-21
Outlook.....III-21
Product Launch.....III-21
Strategic Corporate Development.....III-21
1$75
   B. Market Analytics.....III-22
Table 26: Japanese Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-22
1$200
   Table 27: Japanese Historic Review for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-231$200
   Table 28: Japanese 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart).....III-241$200
   A. Market Analysis.....III-25
Outlook.....III-25
Growth Drivers.....III-25
Table 29: European Drug Delivery Market: Number of Deals Between Pharmaceutical/ Biotechnology Companies and Drug Delivery Companies for 2004 & 2007.....III-25
1$200
   Focus of R&D Shifts to Diabetes Treatment.....III-26
Table 30: Research Activity Distribution in the European Pulmonary Drug Delivery Market (2008): Percentage Share Breakdown of Activity by Therapeutic Area (includes corresponding Graph/Chart).....III-26
European Pulmonary Drug Delivery Market: Drugs In Clinical Pipeline As of
  2007.....III-26
1$200
   DPIs in Europe.....III-27
Product Launches/Developments.....III-27
1$75
   Strategic Corporate Developments.....III-282$125
   Novartis Ag (Switzerland) – A Key European Player.....III-301$75
   B. Market Analytics.....III-31
Table 31: European Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-31
1$200
   Table 32: European Historic Review for Pulmonary Drug Delivery Technologies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-321$200
   Table 33: European 13-Year Perspective for Pulmonary Drug Delivery Technologies by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2003, 2009 and 2015 (includes corresponding Graph/Chart).....III-331$200
   Table 34: European Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-341$200
   Table 35: European Historic Review for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-351$200
   Table 36: European 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart).....III-361$200
   A. Market Analysis.....III-37
Outlook.....III-37
Strategic Corporate Development.....III-37
Valois S.A.S. – A Key Player.....III-37
1$75
   B. Market Analytics.....III-38
Table 37: French Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-38
1$200
   Table 38: French Historic Review for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-391$200
   Table 39: French 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart).....III-401$200
   Market Analysis.....III-41
Table 40: German Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-41
1$200
   Table 41: German Historic Review for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-421$200
   Table 42: German 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart).....III-431$200
   A. Market Analysis.....III-44
Outlook.....III-44
Chiesi Farmaceutici SpA – A Key Player.....III-44
1$75
   B. Market Analytics.....III-45
Table 43: Italian Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-45
1$200
   Table 44: Italian Historic Review for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-461$200
   Table 45: Italian 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart).....III-471$200
   A. Market Analysis.....III-48
Outlook.....III-48
Market Overview.....III-48
Areas of Growth.....III-48
Progress in Drug Delivery.....III-48
1$75
   Product Launches/Developments.....III-491$75
   Strategic Corporate Developments.....III-50
Select Players.....III-50
3$175
   B. Market Analytics.....III-53
Table 46: UK Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-53
1$200
   Table 47: UK Historic Review for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-541$200
   Table 48: UK 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart).....III-551$200
   Market Analysis.....III-56
Table 49: Spanish Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-56
1$200
   Table 50: Spanish Historic Review for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-571$200
   Table 51: Spanish 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart).....III-581$200
   Market Analysis.....III-59
Table 52: Russian Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-59
1$200
   Table 53: Russian Historic Review for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-601$200
   Table 54: Russian 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart).....III-611$200
   Market Analysis.....III-62
Table 55: Rest of Europe Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-62
1$200
   Table 56: Rest of Europe Historic Review for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-631$200
   Table 57: Rest of Europe 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart).....III-641$200
   A. Market Analysis.....III-65
Outlook.....III-65
Regional Snapshot.....III-65
India.....III-65
Nebulizers Market in India: A Quick Primer.....III-65
Dry Powder Inhalers for Children.....III-65
Product Launch.....III-65
1$75
   Strategic Corporate Developments.....III-661$75
   B. Market Analytics.....III-67
Table 58: Asia-Pacific Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-67
1$200
   Table 59: Asia-Pacific Historic Review for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-681$200
   Table 60: Asia-Pacific 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart).....III-691$200
   Market Analysis.....III-70
Table 61: Latin American Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-70
1$200
   Table 62: Latin American Historic Review for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-711$200
   Table 63: Latin American 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart).....III-721$200
   Market Analysis.....III-73
Table 64: Rest of World Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-73
1$200
   Table 65: Rest of World Historic Review for Pulmonary Drug Delivery Technologies by Product Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-741$200
   Table 66: Rest of World 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment - Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart).....III-751$200
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com